Syneos Health, the fully integrated biopharmaceutical solutions organization, introduced FSP 360, an evolved FSP model that provides access to the industry’s to a broad range of traditional and non-traditional FSP capabilities.
“As customers look to consolidate outsourced clinical solutions, traditional static FSP models no longer meet their unique scientific and operational demands,” said Paul Colvin, President, Syneos Health Clinical Solutions.
FSP 360 provides a range of capabilities through combining traditional service functions including monitoring, project management, safety/pharmacovigilance and data services, with non-traditional capabilities including investigator payments, eTMF, site contracts, feasibility and study start up. Engagements are scalable based on where a customer is in their outsourcing evolution.
To learn more www.syneoshealth.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.